Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasacort vs Flixonase in Perennial Allergic Rhinitis
NCT03317015Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of triamcinolone acetonide in perennial allergic rhinitis (PAR), sponsored by Sanofi. Started Nov 2016; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT03317015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317015.